Literature DB >> 14528882

First European case of serotype A MATa Cryptococcus neoformans infection.

M A Viviani, R Nikolova, M C Esposto, G Prinz, M Cogliati.   

Abstract

Entities:  

Mesh:

Year:  2003        PMID: 14528882      PMCID: PMC3016796          DOI: 10.3201/eid0909.020770

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: Cryptococcus neoformans is an opportunistic fungus that causes meningoencephalitis, primarily in immunocompromised patients. However, C. neoformans can also cause illness in apparently normal hosts. The yeast is a heterothallic basidiomycete with two mating types, MAT and MATα identified in all the four serotypes, A, B, C, and D. However, the mating type of serotype A is a rare and recent finding. One strain was isolated from a Tanzanian AIDS patient and a second from the Italian environment; the first was mating defective (,). We report the isolation of a serotype A MAT strain of clinical origin that was characterized by mating at high frequency under standard laboratory conditions. In August 1998, a 45-year-old Hungarian man was admitted to the Laszlo Hospital for Infectious Diseases in Budapest because of septic fever. The patient had a history of hematologic malignancy (Hodgkin disease), which was diagnosed in 1991. He had received several courses of chemotherapy and radiation. After 4 years when his cancer was in remission, in September 1995, the disease recurred (stage IVa) for which he received several more courses of chemotherapy, according to protocols BEAM (carmustine, etoposide, cytarabine, melphalan) and CEP (lomustine, etoposide, prednimustine). In February 1998, another relapse was diagnosed and the patient was given chemotherapy, according to protocol COPP (cyclophosphamide, vincristine, prednisolone, procarbazine) four times. In April 1998, he was hospitalized with herpes zoster infection and treated with acyclovir. At the last admission, in August 1998, he was pancytopenic and had septic fever. Salmonella enteritidis was cultured from his blood. The salmonella septicemia was successfully treated with ceftriaxone. As palliative treatment, he received 4x10 mg vinblastine for his residual disease. On September 30, he became febrile again. Cryptococcus neoformans was isolated from his blood, although cerebrospinal fluid culture and serologic tests were negative. On the right fossa cubitalis, cellulitis and a tender mass were present, although he did not have a history of recent central line or cytostatic treatment on this side. Cryptococcus neoformans was isolated from the sample taken from the mass. Antifungal treatment was started with 600 mg fluconazole per day and continued with amphotericin B, 1 mg/kg/day. The patient died 6 weeks after the isolation of Cryptococcus, probably because of his uncontrolled Hodgkin disease. As far as the physician was aware, the patient had not visited other countries. The strain, isolated from the patient’s blood during the European Confederation of Medical Mycology Cryptococcosis Survey, was sent for typing to the European Convenor. The isolate, IUM 99-3617, was identified as serotype A using Crypto Check serotyping kit from Iatron Laboratories (Tokyo, Japan) and genotyped as VN6 by multiplex polymerase chain reaction (PCR) () by using the primers previously described (,). The fungus was shown to be haploid by cytofluorimetric analysis (). The strain’s fertility was investigated, according to Kwon-Chung (), by crossing the isolate with reference serotype A strains H99 (MATα) and IUM 96-2828 (MAT), and with serotype D congenic strains JEC20 (MAT) and JEC21 (MATα). When cocultured with MATα strains (H99 and JEC21), IUM 99-3617 produced abundant basidiospores. On the contrary, the strain did not mate with JEC20 (MAT D) or with IUM 96-2828 (MAT A). The genotypic and phenotypic characteristics of the fungus were then compared with those of serotype A (MAT and MATα) reference strains. The mating type was analyzed by using PCR amplification of MF, MFα genes, and STE20 and STE20α-specific genes for serotype A and serotype D. PCR reaction was performed as previously reported (). The amplification product showed that IUM 99-3617, like IUM 96-2828, contains only serotype A STE20 and MF genes. To further confirm that IUM 99-3617 was MAT in mating type, MF and STE 20 genes were sequenced by an ABI PRISM 310 automatic sequencer using Big Dye Terminator (Applied Biosystems, Monza, Italy) and the primers, forward and reverse strands previously reported (). The sequences were then aligned with the reported sequences of IUM 96-2828 (,), the Tanzanian isolate 295.1 (), H 99, and the congenic JEC 20 and JEC 21 strains. The IUM 99-3617 sequences were found to be identical to those of IUM 96-2828 and of the Tanzanian isolate 295.1. The MFA and the STE20A sequence of IUM 99-3617 have been submitted to GenBank database (www.ncbi.nlm.gov/Bankit/nhpbankit.cgi) under accession number AY182035 and AY182036, respectively. Virulence studies in the mouse model demonstrate that, like IUM 96-2828, the strain is significantly less virulent than H99. The latter strain caused 100% deaths day 29, while IUM 99-3617 took until day 60 to kill 60% of mice (unpub. data). No difference was observed among the three serotype A strains when virulence factors such as capsule, melanin, phospholipase activity, and ability to grow at 37°C were tested. The MAT of C. neoformans serotype A was long regarded as extinct or as existing in an undiscovered ecologic niche until the recent finding of the clinical and the environmental isolate (,). The existence of MAT in nature is also supported by recent studies designed to established the origin of the serotype AD strains (,). These studies demonstrated that AD strains were diploid or aneuploid hybrids derived from a fusion of serotype A and D parents and that several of them were harboring a serotype A MAT locus. These hybrid strains have been found fairly often in Europe (,). The finding of this isolate provides evidence of the pathogenic role of this rare mating type, emphasizes the critical function of molecular genetic tools in the characterization of C. neoformans populations, and represents an advance in knowledge of this fungal species whose genome is undergoing identification by a worldwide research team.
  7 in total

1.  European Confederation of Medical Mycology (ECMM) prospective survey of cryptococcosis: report from Italy.

Authors: 
Journal:  Med Mycol       Date:  2002-10       Impact factor: 4.076

2.  Determination of ploidy in Cryptococcus neoformans by flow cytometry.

Authors:  R Tanaka; H Taguchi; K Takeo; M Miyaji; K Nishimura
Journal:  J Med Vet Mycol       Date:  1996 Sep-Oct

3.  Origin of Cryptococcus neoformans var. neoformans diploid strains.

Authors:  M Cogliati; M C Esposto; D L Clarke; B L Wickes; M A Viviani
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

4.  Serotype AD strains of Cryptococcus neoformans are diploid or aneuploid and are heterozygous at the mating-type locus.

Authors:  K B Lengeler; G M Cox; J Heitman
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

5.  Identification of the MATa mating-type locus of Cryptococcus neoformans reveals a serotype A MATa strain thought to have been extinct.

Authors:  K B Lengeler; P Wang; G M Cox; J R Perfect; J Heitman
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

6.  Molecular and genetic characterization of a serotype A MATa Cryptococcus neoformans isolate.

Authors:  S M Keller; M A Viviani; M C Esposto; M Cogliati; B L Wickes
Journal:  Microbiology (Reading)       Date:  2003-01       Impact factor: 2.777

7.  Isolation of a Cryptococcus neoformans serotype A MATa strain from the Italian environment.

Authors:  M A Viviani; M C Esposto; M Cogliati; M T Montagna; B L Wickes
Journal:  Med Mycol       Date:  2001-10       Impact factor: 4.076

  7 in total
  8 in total

1.  Cryptococcus neoformans {alpha} strains preferentially disseminate to the central nervous system during coinfection.

Authors:  Kirsten Nielsen; Gary M Cox; Anastasia P Litvintseva; Eleftherios Mylonakis; Stephanie D Malliaris; Daniel K Benjamin; Steven S Giles; Thomas G Mitchell; Arturo Casadevall; John R Perfect; Joseph Heitman
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

2.  Comparative analysis of environmental and clinical populations of Cryptococcus neoformans.

Authors:  Anastasia P Litvintseva; Lori Kestenbaum; Rytas Vilgalys; Thomas G Mitchell
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

3.  Evidence of sexual recombination among Cryptococcus neoformans serotype A isolates in sub-Saharan Africa.

Authors:  Anastasia P Litvintseva; Robert E Marra; Kirsten Nielsen; Joseph Heitman; Rytas Vilgalys; Thomas G Mitchell
Journal:  Eukaryot Cell       Date:  2003-12

4.  Isolates of Cryptococcus neoformans from infected animals reveal genetic exchange in unisexual, alpha mating type populations.

Authors:  Tien Bui; Xiaorong Lin; Richard Malik; Joseph Heitman; Dee Carter
Journal:  Eukaryot Cell       Date:  2008-06-13

Review 5.  Unisexual reproduction.

Authors:  Kevin C Roach; Marianna Feretzaki; Sheng Sun; Joseph Heitman
Journal:  Adv Genet       Date:  2014       Impact factor: 3.880

6.  Many globally isolated AD hybrid strains of Cryptococcus neoformans originated in Africa.

Authors:  Anastasia P Litvintseva; Xiaorong Lin; Irka Templeton; Joseph Heitman; Thomas G Mitchell
Journal:  PLoS Pathog       Date:  2007-08-17       Impact factor: 6.823

Review 7.  Global Molecular Epidemiology of Cryptococcus neoformans and Cryptococcus gattii: An Atlas of the Molecular Types.

Authors:  Massimo Cogliati
Journal:  Scientifica (Cairo)       Date:  2013-01-09

8.  Cryptococcus neoformans Recovered From Olive Trees (Olea europaea) in Turkey Reveal Allopatry With African and South American Lineages.

Authors:  Çağri Ergin; Mustafa Şengül; Levent Aksoy; Aylin Döğen; Sheng Sun; Anna F Averette; Christina A Cuomo; Seyedmojtaba Seyedmousavi; Joseph Heitman; Macit Ilkit
Journal:  Front Cell Infect Microbiol       Date:  2019-11-08       Impact factor: 5.293

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.